Loading
An experimental blood test from Biofidelity in Cambridge that enriches the tumour's mutated DNA before sequencing, so it needs far less sequencing to find leftover cancer.
Enspyre is a ctDNA enrichment method from Biofidelity Ltd of Cambridge, UK. Its analytical study (Labrousse et al., Scientific Reports 2026) used tumour whole-genome sequencing from eight lung cancer patients, ran 72 samples of patient plasma diluted into healthy donor plasma plus eight healthy controls, and reported 100 per cent (6 of 6) detection down to 10 parts per million, residual disease calls as low as 5 parts per million, and no false positives, with a median DNA input of 7.67 ng and a median of 9.6 million read pairs per sample. The authors state that larger studies are needed to establish its analytical performance. Whether it is offered as a clinical test was not confirmed.
A custom capture panel against patient-specific variants from tumour whole-genome sequencing, with a chemistry that enriches mutated DNA so that far fewer sequencing reads are needed; no molecular barcodes are used.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Enspyre" OR ABSTRACT:"Enspyre" OR TITLE:"Biofidelity Enspyre" OR ABSTRACT:"Biofidelity Enspyre") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Enspyre, not a curated reading list.
Shares Tumour-informed versus tumour-naive ctDNA assays, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing and the tags test, mrd.
Shares Tumour-informed versus tumour-naive ctDNA assays, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing and the tags test, mrd.
Shares Tumour-informed versus tumour-naive ctDNA assays, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing and the tags test, mrd.
Shares Tumour-informed versus tumour-naive ctDNA assays, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing and the tags test, mrd.
Shares Tumour-informed versus tumour-naive ctDNA assays, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing and the tags test, mrd.
Shares Tumour-informed versus tumour-naive ctDNA assays, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing and the tags test, mrd.
Shares Tumour-informed versus tumour-naive ctDNA assays, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing and the tags test, mrd.
Shares Tumour-informed versus tumour-naive ctDNA assays, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing and the tag test.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/